Prelude Therapeutics Inc (NASDAQ:PRLD) shares, rose in value on Thursday, April 16, with the stock price up by 5.19% to the previous day’s close as strong demand from buyers drove the stock to $0.81.
Actively observing the price movement in the last trading, the stock closed the session at $0.77, falling within a range of $0.7531 and $0.855. The value of beta (5-year monthly) was 1.339. Referring to stock’s 52-week performance, its high was $6.80, and the low was $0.61. On the whole, PRLD has fluctuated by 9.88% over the past month.
With the market capitalization of Prelude Therapeutics Inc currently standing at about $45.73 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-09.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PRLD’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PRLD currently trading nearly 13.64% and 4.31% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.51, while the 7-day volatility ratio is showing 10.98% which for the 30-day chart, stands at 10.57%. Furthermore, Prelude Therapeutics Inc (PRLD)’s beta value is 1.27, and its average true range (ATR) is 0.08.
A comparison of Prelude Therapeutics Inc (PRLD) with its peers suggests the former has fared considerably weaker in the market. PRLD showed an intraday change of 5.19% in last session, and over the past year, it shrunk by -83.50%%.
Data on historical trading for Prelude Therapeutics Inc (NASDAQ:PRLD) indicates that the trading volumes over the past 10 days have averaged 0.18 and over the past 3 months, they’ve averaged 224.48K. According to company’s latest data on outstanding shares, there are 42.30 million shares outstanding.
Nearly 51.88% of Prelude Therapeutics Inc’s shares belong to company insiders and institutional investors own 37.53% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.38 million shares as on 2025-03-31, resulting in a short ratio of 9.69. According to the data, the short interest in Prelude Therapeutics Inc (PRLD) stood at 1363.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.16 million. The stock has fallen by -36.47% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRLD stock heading into the next quarter.
